1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Astrocytosis in 33 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Parkinson's disease is a neurodegenerative disorder that can, at least partly, be mimicked by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine." | 1.38 | S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. ( Berg, D; Fleckenstein, C; Itohara, S; Lang, JD; Maetzler, W; Martin, HL; Mounsey, RB; Mustafa, S; Sathe, K; Schulte, C; Synofzik, M; Teismann, P; Vukovic, Z, 2012) |
| "Nrf2-knockout mice showed exacerbated gliosis and dopaminergic nigrostriatal degeneration, as determined by immunohistochemical staining of tyrosine hydroxylase in striatum (STR) and substantia nigra (SN) and by HPLC determination of striatal dopamine and 3,4- dihydroxyphenylacetic acid (DOPAC)." | 1.36 | Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. ( Cuadrado, A; Dulak, J; Fernández-Ruiz, J; García, C; Grochot-Przeczek, A; Innamorato, NG; Jazwa, A; Jozkowicz, A; Rojo, AI; Stachurska, A, 2010) |
| ") injection of the neurotoxicant, 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine or 2'-CH(3)-MPTP, to postnatal day 4 (PD4) mice caused acute and transient gliosis in the brain, which can be noninvasively monitored during a course of 8 h immediately after the dosing [Ho, G." | 1.35 | Molecular imaging reveals a correlation between 2'-CH3-MPTP-induced neonatal neurotoxicity and dopaminergic neurodegeneration in adult transgenic mice. ( Ho, G; Kng, YL; Kumar, S; Zhang, C; Zhuo, L, 2008) |
| "Neuroinflammation is a hot topic in contemporary neuroscience." | 1.35 | Defining "neuroinflammation". ( Miller, DB; O'Callaghan, JP; Sriram, K, 2008) |
| "Celastrol is a potent anti-inflammatory and antioxidant compound extracted from a perennial creeping plant belonging to the Celastraceae family." | 1.33 | Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. ( Beal, MF; Calingasan, NY; Chen, J; Cleren, C, 2005) |
| "Although the pathogenesis of Parkinson's disease (PD) remains unknown, it appears that microglial activation is associated with enhanced neurodegeneration in animal models of PD as well as in PD patients." | 1.33 | Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. ( Hong, JS; Kovacs, M; Liu, J; Ma, T; McLaughlin, P; Zhang, J; Zhang, W; Zhou, Y, 2006) |
| "The psychostimulant methamphetamine (MA) is toxic to nigro-striatal dopaminergic terminals in both experimental animals and humans." | 1.32 | Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. ( Battaglia, G; Busceti, CL; De Blasi, A; Fornai, F; Lembo, G; Nicoletti, F, 2003) |
| " We investigated whether minocycline would protect against toxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxin that selectively destroys nigrostriatal dopaminergic (DA) neurons and produces a clinical state similar to Parkinson's disease (PD) in rodents and primates." | 1.32 | Minocycline enhances MPTP toxicity to dopaminergic neurons. ( Albers, DS; Beal, MF; Browne, SE; Chirichigno, JW; Gregorio, J; Joh, TH; Lorenzl, S; Shimizu, Y; Shin, DH; Sugama, S; Yang, L, 2003) |
| "Reactive gliosis, which occurs in response to neurodegeneration was not evident by immunocytochemistry but was detected by enzyme-linked immunosorbent assay, where glial fibrillary acidic protein (GFAP) was increased to 130% of control in cortex, hippocampus, and brain stem 48 to 72 h post-treatment." | 1.32 | Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine. ( Andrews, AM; Chisnell, AC; Luellen, BA; Miller, DB; Murphy, DL; O'Callaghan, JP, 2003) |
| " Chronic administration of low doses of MPTP resulted in animals with stable cognitive deficits without overt parkinsonian motor symptoms." | 1.32 | Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. ( Kulak, JM; Schneider, JS, 2004) |
| "These results support reactive gliosis as a means of striatal compensation for dopamine loss." | 1.32 | Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. ( Beales, M; Dervan, AG; McBean, GJ; Meredith, GE; Meshul, CK; Moore, C; Snyder, AK; Totterdell, S, 2004) |
| "The pathogenic mechanisms underlying idiopathic Parkinson's disease (PD) remain enigmatic." | 1.31 | Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. ( Benkovic, SA; Luster, MI; Matheson, JM; Miller, DB; O'Callaghan, JP; Sriram, K, 2002) |
| "The onset of reactive gliosis then was verified by Northern blot analysis of glial fibrillary acidic protein (GFAP) mRNA and qualified by enzyme-linked immunosorbent assay (ELISA) of GFAP (protein)." | 1.30 | The MAP kinase cascade is activated prior to the induction of gliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of dopaminergic neurotoxicity. ( Martin, PM; Mass, MJ; O'Callaghan, JP, 1998) |
| "Reactive gliosis was observed throughout the mouse striatum but not in the substantia nigra." | 1.27 | Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. ( Denaro, FJ; Schneider, JS, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 21 (63.64) | 29.6817 |
| 2010's | 9 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El Massri, N | 2 |
| Johnstone, DM | 2 |
| Peoples, CL | 1 |
| Moro, C | 2 |
| Reinhart, F | 1 |
| Torres, N | 2 |
| Stone, J | 2 |
| Benabid, AL | 2 |
| Mitrofanis, J | 2 |
| Viana, SD | 1 |
| Fernandes, RC | 1 |
| Canas, PM | 1 |
| Silva, AM | 1 |
| Carvalho, F | 1 |
| Ali, SF | 1 |
| Fontes Ribeiro, CA | 1 |
| Pereira, FC | 1 |
| Darlot, F | 1 |
| Agay, D | 1 |
| Chabrol, C | 1 |
| Bagga, P | 1 |
| Crescenzi, R | 1 |
| Krishnamoorthy, G | 1 |
| Verma, G | 1 |
| Nanga, RP | 1 |
| Reddy, D | 1 |
| Greenberg, J | 1 |
| Detre, JA | 1 |
| Hariharan, H | 1 |
| Reddy, R | 1 |
| Ho, G | 3 |
| Kumar, S | 3 |
| Zhang, C | 1 |
| Kng, YL | 2 |
| Zhuo, L | 3 |
| O'Callaghan, JP | 4 |
| Sriram, K | 2 |
| Miller, DB | 3 |
| Moon, M | 1 |
| Kim, HG | 1 |
| Hwang, L | 1 |
| Seo, JH | 1 |
| Kim, S | 2 |
| Hwang, S | 1 |
| Lee, D | 1 |
| Chung, H | 1 |
| Oh, MS | 1 |
| Lee, KT | 1 |
| Park, S | 1 |
| Bian, MJ | 1 |
| Li, LM | 1 |
| Yu, M | 1 |
| Fei, J | 1 |
| Huang, F | 1 |
| Ke, Z | 1 |
| Chan, HH | 1 |
| Suhaimi, NA | 1 |
| Zhang, Y | 2 |
| Kuroiwa, H | 1 |
| Yokoyama, H | 2 |
| Kimoto, H | 1 |
| Kato, H | 2 |
| Araki, T | 3 |
| Innamorato, NG | 1 |
| Jazwa, A | 1 |
| Rojo, AI | 1 |
| García, C | 1 |
| Fernández-Ruiz, J | 1 |
| Grochot-Przeczek, A | 1 |
| Stachurska, A | 1 |
| Jozkowicz, A | 1 |
| Dulak, J | 1 |
| Cuadrado, A | 1 |
| Sathe, K | 1 |
| Maetzler, W | 1 |
| Lang, JD | 1 |
| Mounsey, RB | 1 |
| Fleckenstein, C | 1 |
| Martin, HL | 1 |
| Schulte, C | 1 |
| Mustafa, S | 1 |
| Synofzik, M | 1 |
| Vukovic, Z | 1 |
| Itohara, S | 1 |
| Berg, D | 1 |
| Teismann, P | 1 |
| Matheson, JM | 1 |
| Benkovic, SA | 1 |
| Luster, MI | 1 |
| Muramatsu, Y | 1 |
| Kurosaki, R | 1 |
| Watanabe, H | 1 |
| Michimata, M | 1 |
| Matsubara, M | 1 |
| Imai, Y | 1 |
| Battaglia, G | 1 |
| Fornai, F | 1 |
| Busceti, CL | 1 |
| Lembo, G | 1 |
| Nicoletti, F | 1 |
| De Blasi, A | 1 |
| Yang, L | 1 |
| Sugama, S | 1 |
| Chirichigno, JW | 1 |
| Gregorio, J | 1 |
| Lorenzl, S | 1 |
| Shin, DH | 1 |
| Browne, SE | 1 |
| Shimizu, Y | 1 |
| Joh, TH | 1 |
| Beal, MF | 2 |
| Albers, DS | 1 |
| Luellen, BA | 1 |
| Chisnell, AC | 1 |
| Murphy, DL | 1 |
| Andrews, AM | 1 |
| Kulak, JM | 1 |
| Schneider, JS | 2 |
| Barcia, C | 1 |
| Sánchez Bahillo, A | 1 |
| Fernández-Villalba, E | 1 |
| Bautista, V | 1 |
| Poza Y Poza, M | 1 |
| Fernández-Barreiro, A | 1 |
| Hirsch, EC | 1 |
| Herrero, MT | 1 |
| Dervan, AG | 1 |
| Meshul, CK | 1 |
| Beales, M | 1 |
| McBean, GJ | 1 |
| Moore, C | 1 |
| Totterdell, S | 1 |
| Snyder, AK | 1 |
| Meredith, GE | 1 |
| Khan, HA | 1 |
| Hébert, G | 1 |
| Mingam, R | 1 |
| Arsaut, J | 1 |
| Dantzer, R | 1 |
| Demotes-Mainard, J | 1 |
| Ostergren, A | 1 |
| Fredriksson, A | 1 |
| Brittebo, EB | 1 |
| Cleren, C | 1 |
| Calingasan, NY | 1 |
| Chen, J | 1 |
| McLaughlin, P | 1 |
| Zhou, Y | 1 |
| Ma, T | 1 |
| Liu, J | 1 |
| Zhang, W | 1 |
| Hong, JS | 1 |
| Kovacs, M | 1 |
| Zhang, J | 1 |
| Fan, Y | 1 |
| Kong, H | 1 |
| Shi, X | 1 |
| Sun, X | 1 |
| Ding, J | 1 |
| Wu, J | 1 |
| Hu, G | 1 |
| Takagi, S | 1 |
| Watanabe, Y | 1 |
| Martin, PM | 1 |
| Mass, MJ | 1 |
| Kay, JN | 1 |
| Blum, M | 1 |
| Ikeda, K | 1 |
| Kurokawa, M | 1 |
| Aoyama, S | 1 |
| Kuwana, Y | 1 |
| Forno, LS | 1 |
| DeLanney, LE | 1 |
| Irwin, I | 1 |
| Di Monte, D | 1 |
| Langston, JW | 1 |
| Denaro, FJ | 1 |
1 review available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Astrocytosis
| Article | Year |
|---|---|
Astrocytes and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biotransformation; Dopamine; Glio | 1992 |
32 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Astrocytosis
| Article | Year |
|---|---|
The effect of different doses of near infrared light on dopaminergic cell survival and gliosis in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Caudate Nucleus; Cell Count; Cell | 2016 |
Presymptomatic MPTP Mice Show Neurotrophic S100B/mRAGE Striatal Levels.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aldehydes; Animals; Corpus Striatum; Disease Models, A | 2016 |
Near-infrared light treatment reduces astrogliosis in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Calcium-Binding Protein | 2016 |
Mapping the alterations in glutamate with GluCEST MRI in a mouse model of dopamine deficiency.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Brain Chemistry; Dopamine; Dopami | 2016 |
Molecular imaging reveals a correlation between 2'-CH3-MPTP-induced neonatal neurotoxicity and dopaminergic neurodegeneration in adult transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Animals, Newborn; Brain; Disease Model | 2008 |
Defining "neuroinflammation".
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Bacterial Agents; Antibodies, Phospho-Sp | 2008 |
Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Animals, Newborn; Cells | 2009 |
Elevated interleukin-1beta induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Aging; Animals; Biomarkers; Cytokines; Di | 2009 |
Imidazolium salt (DBZIM) reduces gliosis in mice treated with neurotoxicant 2'-CH(3) -MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Dopamine Antagonists; Eye; G | 2011 |
Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; C | 2010 |
Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Dopamin | 2010 |
In vivo imaging of retinal gliosis: a platform for diagnosis of PD and Screening of anti-PD compounds.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Progression; Dopamine Agents; Genotyp | 2010 |
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Case-Control Studies; Cell Line; Diseas | 2012 |
Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Cytoprotection; Dopamine; Do | 2002 |
Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Dopamine; Down-Regula | 2003 |
Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adrenergic alpha-1 Rec | 2003 |
Minocycline enhances MPTP toxicity to dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dose-R | 2003 |
Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Brain Chemistry; Dopamine; Enzyme | 2003 |
Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptation, Physiological; alpha7 Nicotinic Acetylchol | 2004 |
Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Calbindins; Corpus St | 2004 |
Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biological Transport; Cell Count; | 2004 |
Detection and semi-quantitative determination of low abundance GFAP mRNA in mouse brain by capillary electrophoresis coupled with laser-induced fluorescence.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Brain Chemistry; Electrophoresis, | 2004 |
Cellular distribution of interleukin-1alpha-immunoreactivity after MPTP intoxication in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biomarkers; Corpus Striatum; Dise | 2005 |
Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Carbolines; Caspase 3; Caspases; D | 2006 |
Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Antioxidants; Cell | 2005 |
Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cells, Cultured; Coculture Techniques; Dinopr | 2006 |
Hypersensitivity of aquaporin 4-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine and astrocytic modulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aquaporin 4; Dose-Response Relationship, Drug | 2008 |
Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoprotectio | 2008 |
The MAP kinase cascade is activated prior to the induction of gliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of dopaminergic neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium-Calmodulin-Dependent Protein Kinases; | 1998 |
Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Brain Diseases; Cell Differentiat | 2000 |
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antineoplastic A | 2002 |
Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Brain; Cats; Dopamine; Glial Fibr | 1988 |